DUBLIN–(BUSINESS WIRE)–The “Natural Killer (NK) cell therapy – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
The publisher’s, “Natural Killer (NK) cell therapy – Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in Natural Killer (NK) cell therapy pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
“Natural Killer (NK) cell therapy – Pipeline Insight, 2022” report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Natural Killer (NK) cell therapy pipeline landscape is provided which includes the disease overview and Natural Killer (NK) cell therapy treatment guidelines.
The assessment part of the report embraces, in depth Natural Killer (NK) cell therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Natural Killer (NK) cell therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Natural Killer (NK) cell therapy R&D. The therapies under development are focused on novel approaches to treat/improve Natural Killer (NK) cell therapy.
Natural Killer (NK) cell therapy Emerging Drugs Chapters
This segment of the Natural Killer (NK) cell therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Natural Killer (NK) cell therapy: Therapeutic Assessment
This segment of the report provides insights about the different Natural Killer (NK) cell therapy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Natural Killer (NK) cell therapy
There are approx. 100+ key companies which are developing the therapies for Natural Killer (NK) cell therapy. The companies which have their Natural Killer (NK) cell therapy drug candidates in the most advanced stage, i.e. Phase III include, Nektar therapeutics.
Natural Killer (NK) cell therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Natural Killer (NK) cell therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Natural Killer (NK) cell therapy drugs.
Key Questions
- How many companies are developing Natural Killer (NK) cell therapy drugs?
- How many Natural Killer (NK) cell therapy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Natural Killer (NK) cell therapy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Natural Killer (NK) cell therapy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Natural Killer (NK) cell therapy and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Topics Covered:
Introduction
Executive Summary
Natural Killer (NK) cell therapy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
- NKTR-214: Nektar therapeutics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
- CellProtect: XNK Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I/II)
- Comparative Analysis
- Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
- Natural Killer (NK) cell therapy – Key Companies
- Natural Killer (NK) cell therapy – Key Products
- Natural Killer (NK) cell therapy – Unmet Needs
- Natural Killer (NK) cell therapy – Market Drivers and Barriers
- Natural Killer (NK) cell therapy – Future Perspectives and Conclusion
- Natural Killer (NK) cell therapy – Analyst Views
- Natural Killer (NK) cell therapy – Key Companies
Appendix
Companies Mentioned
- ImmunityBio
- Cantargia
- CureTech
- Dynavax
- Cellid
- Abivax
- Affimed
- Celularity
- Glycostem Therapeutics (IPD Therapeutic)
- SYNIMMUNE
- Celyad
- Acepodia
- Allife Medical Science and Technology
- Bright Path Biotherapeutics
- Cytovia Therapeutics
- CytoImmune Therapeutics
- Exacis Biotherapeutics
- Novocellbio
- Kuur Therapeutics (Former name: Cell Medica)
- Fate Therapeutics
- Feldan Therapeutics
- iCell Gene Therapeutics
- Innate Pharma
- Nkarta Therapeutics
- Surface Oncology
- Kiadis Pharma
- Vycellix
- INmune Bio
- CiMass
- Glycostem
- Five Prime Therapeutics
- Multimmune GmbH
- Ambicion
- Bellicum Pharmaceuticals
- CARsgen therapeutics
- Kuur Therapeutics
- Celyad
- Dragonfly Therapeutics
- GamidaCell
- NantKwest
- Asclepius Technology Company
- AffimedTherapeutics
- Apceth Biopharma
- Zelluna Immunotherapy
- Catamaran Bio
- ONK Therapeutics
- Orgenesis
- Navrogen
- NKMAX
- Nektar Therapeutics
- Affimed Therapeutics
- HerbiCell
- Bristol-Myers Squibb
- CellProtect Nordic Pharmaceuticals
- CytoVac
- Green Cross Corporation
- NantKwest
- PersonGen BioTherapeutics (Suzhou)
- GT Biopharma (formerly Oxis International Inc.)
- Nektar Therapeutics
- Artiva Biotherapeutics
- Senti Biosciences
- oNKo-innate
- Affimed Therapeutics
- Agenus
- Chongqing Sidemu Biotechnology
- NKGen Biotech
- Caribou Biosciences
- Gamida-Cell
- Wugen
- Molmed
- Century Therapeutics
- KSQ Therapeutics
- GT Biopharma
- Shoreline Biosciences
- Indapta Therapeutics
- HebeCell
- Sorrento therapeutics
- Appia Bio
- Cellatoz Therapeutics
- Sanofi
- Glycotype
- CiMaas
- CoImmune
- Editas Medicine
- Healios
- Chimeric Therapeutics
- Rubius Therapeutics
- Oncternal Therapeutics
- MedXCell
- MiNK Therapeutics
- Phio Pharmaceuticals
- Biohaven Pharmaceuticals
- Lava therapeutics
- Allogene Therapeutics/Notch Therapeutics
- Onward therapeutics
- Miltenyi Biotec
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/4x5no3.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900